Virally regulated HIV-1 particles were expressed from DNA plasmids encoding Gag, protease, reverse transcriptase, Vpu, Tat, Rev, and Env. The sequences for integrase, Vpr, Vif, Nef, and the long terminal repeats (LTRs) were deleted. Mutations were engineered into the VLP genome to produce particles deficient in activities associated with viral reverse transcriptase, RNase H, and RNA packaging. Each plasmid efficiently secreted particles from primate cells in vitro and particles were purified from the supernatants and used as immunogens. Mice (BALB/c) were vaccinated intranasally (day 1 and weeks 3 and 6) with purified VLPs and the elicited immunity was compared to particles without Env (Gag p55 ), to soluble monomeric Env gp120 , or to soluble trimerized Env gp140 . Only mice vaccinated with VLPs had robust anti-Env cellular immunity. In contrast, all mice had high titer anti-Env serum antibody (IgG). However, VLP-vaccinated mice had antisera that detected a broader number of linear Env peptides, had anti-Env mucosal IgA and IgG, as well as higher titers of serum neutralizing antibodies. VLPs elicited high titer antibodies that recognized linear regions in V4-C5 and the ectodomain of gp41, but did not recognize V3. These lentiviral VLPs are effective mucosal immunogens that elicit broader immunity against Env determinants in both the systemic and mucosal immune compartments than soluble forms of Env.
Introduction
The ultimate goal of an AIDS vaccine is to elicit potent cellular and humoral immune responses that will result in enduring, broadly protective immunity (reviewed in Slobod et al., 2005; Spearman, 2003) . While much effort has focused on elucidating the mechanisms and specificity of cellular immune responses, less is known about virus-specific antibody responses. It has been well established that cellular immune responses mediate viral control during the primary infection and maintain the viral set point in chronic infection (Hamer, 2004) . However, administration of human monoclonal antibodies passively protects against virus exposure in the HIV-1/ chimpanzee (Conley et al., 1996; Murthy et al., 1998) , SIV/ monkey (Gardner et al., 1995; Haigwood et al., 1996) and SHIV/monkey models (Foresman et al., 1998; Li et al., 1997; Mascola et al., 1999 Mascola et al., , 2000 Shibata et al., 1999) , demonstrating the ability of antibody alone to mediate protection against pathogenic virus infection. Thus, one goal of an AIDS vaccine should be to elicit robust and broadly reactive cellular and humoral immunity in both systemic and mucosal immune compartments, thereby maximizing the potential for protection from variant HIV-1 strains by different routes of exposure.
A particle-based immunogen, such as a non-infectious viruslike particle (VLP), is a promising candidate for a safe and effective AIDS vaccine. VLPs are defined as self-assembling, non-replicating, non-pathogenic, and preferably genomeless particles that are similar in size and conformation to intact infectious virions. There are multiple combinations of viral proteins that may be used to generate VLPs, however, they must contain Gag gene products in order to assemble and bud from cells. Env gp160 may also be processed and incorporated as trimeric spikes protruding from the surface of these particles. The VLP used in this study is expressed from a virally regulated, multi-gene DNA plasmid. However, unlike many other VLPs currently being tested in AIDS vaccine research, our VLP-DNA plasmids can express multiple viral gene products from the same cell intracellularly and secrete these VLPs extracellularly from primate cells from a single DNA plasmid in vivo (Young and Ross, 2005; Young et al., 2004) .
Other multi-gene-based VLP expression systems have been developed to express VLPs from DNA plasmids (Ellenberger et al., , 2005 Smith et al., 2004; Hammonds et al., 2003) . While these approaches successfully elicited cellular immunity against VLP antigens, these VLPs elicited limited binding antibody and little, if any, neutralizing antibodies, even after multiple vaccinations (Amara et al., 2001; Ellenberger et al., 2004 Ellenberger et al., , 2005 Smith et al., 2004; Wyatt et al., 2004) . In addition, low to undetectable cellular or humoral immune responses were observed at mucosal sites. The lack of a robust antibody responses may be due, in part, to the in vivo production of particles that were primarily retained intracellularly and therefore these viral antigens were processed for MHC class I presentation. Lastly, the lack of neutralizing antibodies in these studies may be a result of (1) the elicitation of low antibody titers or (2) the specific envelope chosen for incorporation into these particles.
Over the past 20 years, multiple AIDS vaccine strategies have been developed, but each has failed to protect against disease (for reviews, see Egan, 2004; Haigwood, 2004; Sauter et al., 2005; Slobod et al., 2005; Spearman, 2003) . Early trials using monomeric HIV-1 envelopes, while eliciting high titer antibodies, failed to elicit antibodies capable of neutralizing HIV-1 in vitro. However, the role of Env appears critical for the induction of protective immunity in recent AIDS vaccines (Amara et al., 2002; Letvin et al., 2004) , which may point to other antibody and cellular immune mechanisms, such as antibody-dependent cytotoxicity (ADCC) (Forthal et al., 2001; Forthal et al., 1999; Gomez-Roman et al., 2005; Peng et al., 2005) , as important mediators of protection. Inclusion of Env in a multi-component AIDS vaccine results in lower viral set points and higher CD4 counts following challenge compared to the same vaccines lacking Env (Amara et al., 2002; Letvin et al., 2004) .
Envelope on the native virion is predicted to form a trimer (Farzan et al., 1998; Kwong et al., 1998; . Thus, while neutralizing antibody responses appear to be an important component to elicit in an AIDS vaccine, they tend to recognize highly conformational epitopes on Env that may not be immunogenic in vivo. The inability of monomeric envelopes to elicit neutralizing antibodies is most likely due to differences in structure between monomeric forms of gp120 and oligomeric forms of envelope as they are expressed on the surface of a virus particle. Several vaccine strategies have incorporated an oligomeric/trimeric form of Env in order to elicit cross-reactive immunity that neutralizes viral infection (Beddows et al., 2005; Bower et al., 2004 Bower et al., , 2005 Sanders et al., 2002; Yang et al., 2000 Yang et al., , 2002 . The expression of trimeric Env on the surface of a particle does appear to elicit higher titers of neutralizing antibodies than soluble gp120 following intramuscular injection (Hammonds et al., 2005) , even though much of the neutralizing antibodies were directed at membrane embedded cellular proteins.
To overcome this problem, soluble trimers of Env have been developed. Soluble, stabilized Env trimers are hypothesized to mimic the trimeric structure of the envelope on the native virion and possibly induce conformationally dependent antibodies that recognize epitopes present only on native virion-associated envelopes. Several of these trimeric Env immunogens do elicit slightly higher titers of neutralizing antibodies than monomeric Env gp120 (Barnett et al., 2001; Bower et al., 2004; VanCott et al., 1997; Yang et al., 2001) . Often, these oligomeric Env proteins are produced by eliminating the natural cleavage site recognized by cellular proteases (Chakrabarti et al., 2005; Srivastava et al., 2002; Yang et al., 2002; Zhang et al., 2001) . The lack of elicited high titer, broadly reactive neutralizing antibodies by these immunogens is associated with the elicitation of primarily nonneutralizing antibodies Schulke et al., 2002; Si et al., 2003) , because these uncleaved envelopes are in non-native forms or are processed through different cellular pathways than cleaved forms of Env (Adams and Scheid, 2001; McCune et al., 1988; . Therefore, in this study, mice were vaccinated with soluble envelopes (monomeric Env gp120 or trimeric Env gp140 ) or trimeric envelopes that were membrane retained on an HIV-1 VLP to determine if the form(s) and presentation of envelope to the immune system influence the elicited immunity.
Results

In vitro expression and particle purification of virus-like particles
An HIV-1 virus-like particle expressing plasmid was constructed from a proviral genome, as previously described (Young et al., 2004) . The full-length HIV-1 VLP genome expressed Gag, protease (PR), reverse transcriptase (RT), Vpu, Tat, Rev, and Env gene products to produce a PR-processed, but immature particle. A second VLP was expressed from a Gag only codon-optimized sequence that produced an unprocessed, immature particle. Plasmids expressing monomeric Env gp120 or trimeric Env gp140 envelopes have been previously described (Bower et al., 2004) .
Expression of VLPs was determined in vitro following transient transfection of primate (COS) cells with each DNA plasmid. Cell culture supernatants and lysates containing Gag gene products were detected following SDS-PAGE and Western blot (Young et al., 2004) . Particles were purified from the supernatants of transiently transfected cells by ultracentrifugation (20-60% sucrose gradient), and collected fractions were analyzed for particle composition and stability. VLPs banded in the same sucrose fractions (32-40% sucrose, 1.14-1.18 g/cm 3 ), as previously described for wild-type virions ( Fig. 1) (Chertova et al., 2002; Dettenhofer and Yu, 1999; Mouland et al., 2000; Tang et al., 2003; Wang et al., 1998) .
Cell-mediated immunity elicited by VLPs
Mice (BALB/c) were vaccinated intranasally with (1) purified HIV-1 VLPs, (2) Gag p55 only particles, (3) purified soluble trimerized Env gp140 , or (4) soluble monomeric Env gp120 , at day 1 and weeks 3 and 6. Collected splenocytes were stimulated in vitro with peptides specific for HIV-1 Gag, Pol or Env (Table 1 ). Mice vaccinated with the HIV-1 VLPs had a robust cell-mediated immune response against Gag, Pol and Env. Four pools of Env peptides were used to detect splenocyte responses (mINF-γ) specifically against the C1 region, the V3 region, a pool representing the gp120 region of Group M consensus Env, or a pool representing the gp41 region of Group M consensus Env. Mice vaccinated with soluble Envs had a reduced cellular response, as measured by mINF-γ production, compared to mice vaccinated with HIV VLPs (Fig. 2) . Cellular responses against Gag elicited by HIV VLPs were statistically similar to the responses elicited by Gag only particles. Age-matched mice, as well as splenocytes from mice vaccinated with VLPs and stimulated with an irrelevant peptide or unstimulated, had few mINF-γ secreting splenocytes (0-7 spots) following in vitro re-stimulation (data not shown).
VLP-bound envelope efficiently elicits anti-Env antibody
All mice vaccinated with HIV VLPs or soluble envelopes had anti-Env antibodies against gp120 following the first inoculation, which increased after each subsequent vaccination. Mice vaccinated with soluble envelopes were administered a 10-to 100-fold higher dose of envelope than mice vaccinated with membrane-bound envelope on the surface of the VLPs (Fig. 3A) . However, even though the amount of Env on the VLP was similar to the 1 μg dose of soluble envelope, the VLPs elicited a log higher titer of anti-Env antibodies (Fig. 3B ). Mice vaccinated with VLPs had higher IgG 2a titers compared to IgG 1 , indicating a T helper type 1 immune response. In contrast, mice vaccinated with soluble Env gp140 or Env gp120 elicited a predominately IgG 1 antibodies, indicating a predominately T helper 2 response.
Both anti-Env IgG and IgA were detected in mice vaccinated with VLPs (Fig. 4) . The highest titers were detected in the lungs, 160  80  40  40  40  10  gp140  80  10  10  10  10  10  10  gp120  80  10  10  10  10  10  10 a Antisera from vaccinated mice was incubated with each virus pseudotyped with the indicated viral envelopes.
b CAAN = CAAN5342.A2. c THRO = THRO4156.18. d IC50 on sera collected at week 10. Inhibition of viral infection of TZM-bl cells was assessed by the additional reduction in infectivity beyond the background of sera from age-matched naïve mice. Fig. 2 . Elicitation of interferon-γ producing splenocytes. ELISpots were performed on isolated splenocytes from vaccinated mice collected at week 8. Cells (1 × 10 6 ) were stimulated independently with peptides representing four different regions of Env: (a) the first constant region of gp120 (C1), (b) the V3 loop region of Env (V3), (c) the entire gp120 region (gp120), or (d) the entire gp41 region (gp41). Peptides in the gp120 and gp41 peptide pools were 15mers overlapping by 11 amino acids. The C1 and V3 pools are described in the Materials and methods. Splenocytes were also stimulated independently with pools of peptides representing Gag or Pol regions. Following stimulation, cells were assayed for mINF-γ. Nef peptides were used as a non-specific negative control. Splenocytes stimulated with PMA/ionomycin had colonies too numerous to count. but anti-Env antibodies were also detected in the secretions of the vagina and intestine, albeit at lower titers (Fig. 4 ). Mice vaccinated with soluble envelopes (10 μg) generally had statistically lower titers than VLP-vaccinated mice and mice vaccinated with a 1 μg dose of soluble Envs had undetectable mucosal anti-Env antibodies.
Virus-like particles broaden the anti-Env antibody responses
Serum samples were assayed for the ability to recognize individual, overlapping peptides representing the entire Env gp160 . Sera collected from all vaccinated mice recognized greater than 50% of all the peptides at low levels (< 0.2 O.D, less than 3-fold over background). However, mice vaccinated with VLPs recognized a larger number of Env-specific peptides at higher titers compared to mice vaccinated with soluble envelopes (Fig. 5) . Sera from mice vaccinated with soluble envelopes bound fewer than 9 peptides with a titer that was greater than 3-fold over background (non-specific peptides, as well as sera from naïve mice) (Figs. 5A and B).
In contrast, collected sera from HIV-1 VLP-vaccinated mice recognized 40 peptides with a titer that was 3-fold over background (Fig. 5C ). Sera from VLP-vaccinated mice recognized peptides in both gp120 and gp41 and sera from mice vaccinated with gp140, which contained the ectodomain of gp41, did not recognize any of the peptides representing gp140.
Even though peptides were recognized by sera from VLPvaccinated mice throughout Env at high titers, there did appear to be hotspots of recognition. Peptides overlapping the cleavage site, representing the V4-C5 regions in gp120 and the amino terminal region of gp41, were specifically recognized by this serum (Fig. 5) . Interestingly, sera from VLP-vaccinated mice also recognized peptides in gp41 that overlap the highly cross-reactive Kennedy epitope. A few specific peptides were recognized by sera from VLPvaccinated mice to regions in C2. Lower titer antibodies (2-to 3-fold over background; <0.2 O.D.) recognized several peptides in V1, V2, and C2, but few high titer antibodies (greater than 3-fold over background; > 0.2 O.D.) recognized peptides in V1 or V2 and no peptides were detected to V3. Sera from mice vaccinated with Env gp120 did detect three V3-specific peptides at high titers, but Env gp140 -vaccinated mice did not. In contrast, numerous peptides in the V1, V2, C2, and V3 regions were recognized by antisera at lower titers (less than 3-fold) from mice vaccinated with soluble envelopes (data not shown).
Neutralization activity
Sera were examined for the ability to neutralize virus infection in vitro (Montefiori, in press) against both neutralization-sensitive and neutralization-resistant viral isolates (Table 1) . Sera from mice vaccinated intranasally with HIV-1 VLPs had antibodies that neutralized both homologous and heterologous virus isolates (50% inhibition, no IC90 values detected). The R5 isolates representing early transmission (CAAN5342.A2, PVO.4, and THRO4156.18) were more difficult to neutralize than YU-2 or ADA. The dual-tropic isolate, 89.6, was consistently the more easily neutralized isolate and the only isolate neutralized with sera from mice vaccinated with soluble envelopes (Table 1) . Sera from mice vaccinated with Gag p24 only did not neutralize any of the viral isolates (data not shown). In addition, the antibodies in the sera from VLP-vaccinated mice were specific for Env, since the sera from these mice neutralized viruses with HIV-1 Env and did not neutralize viruses pseudotyped the MuLV Env (Table 1) .
Discussion
In this study, HIV-1 virus-like particles were expressed from a single gene insert lacking the sequences for LTRs, IN, Vpr, Vif, and Nef that was engineered with safety mutations in CA p24 and RT to prevent viral RNA packaging and reverse transcriptase activity (Young et al., 2004) . The VLPs were produced from a virally regulated modified proviral genome that resulted in a self-assembling, non-replicating, nonpathogenic, genomeless particle that was similar in size and conformation to intact virions. These VLP immunogens can be administered as purified particles or expressed in vivo from DNA plasmids/viral vectors (for reviews, see references (Doan et al., 2004; Young and Ross, 2003) ). Only a few systems have been developed that utilize the viral regulatory mechanisms of a lentiviral genome to express particles in primate cells (Smith et al., 2003; Young et al., 2004) .
Mice inoculated intranasally with these HIV-1 VLPs elicited robust cellular responses to Gag, Pol, and Env gene products (Fig. 2) . Soluble forms of Env were administered at doses 10-to 100-fold higher than the Env on the VLP, yet elicited few cellular responses. Both VLPs and soluble envelopes did elicit robust anti-Env serum antibody (Fig. 3) , however, mice vaccinated with VLPs elicited antibodies that recognized a broader number of Env-specific peptides at higher titers than sera from mice vaccinated with soluble envelopes (Fig. 5) . In addition, only mice vaccinated with VLPs had high mucosal anti-Env antibodies (Fig 4) . Despite similar anti-Env IgG serum titers (Fig. 3) , only mice vaccinated with VLPs had antibodies that blocked viral infection of neutralization-resistant viruses in an in vitro neutralization assay (Table 1) . Therefore, the presentation of native forms of envelope in the context of a viral membrane to the immune system elicited significantly broader immunity than soluble forms of envelope following mucosal vaccination.
The goal of this study was to determine if envelope, presented to the immune system on the surface of a viral particle, is a more effective immunogen than soluble forms of Env. The role of Env appears critical for the induction of protective efficacy by recent AIDS vaccines (Amara et al., 2002; Letvin et al., 2004) . Non-human primates immunized with Gag only vaccines do not control viral infection as well as the same vaccine that included Env (Amara et al., 2002) . However, the specific immune mechanism(s) associated with Env in those vaccines has not been determined, but most likely is associated with anti-Env cellular and antibody responses.
Envelope on the native virion is predicted to form a trimer (Chan et al., 1997; Farzan et al., 1998; Hill et al., 1996; Tan et al., 1997) . Therefore, our laboratory and others have used soluble, oligomeric/trimeric forms of Env to mimic the proposed native trimeric structure of Env on the viral membrane in order to elicit cross-reactive immunity and induce conformationally dependent antibodies that recognize epitopes present only on the native virion-associated envelopes (Beddows et al., 2005; Bower et al., 2004; Center et al., 2001; Grundner et al., 2005; Rao et al., 2004; Sanders et al., 2002; Yang et al., 2000 Yang et al., , 2002 . These uncleaved oligomeric Env proteins do elicit marginally higher neutralizing antibody titers than monomers of Env gp120 when administered parenterally (Barnett et al., 2001; Bower et al., 2004; VanCott et al., 1997; Yang et al., 2001 ). The lack of high titer, broadly reactive neutralizing antibodies elicited by these immunogens is associated with the elicitation of primarily non-neutralizing antibodies Schulke et al., 2002; Si et al., 2003) .
Even though all the vaccines in this study elicited serum antiEnv antibodies, the envelope-bound VLPs elicited higher titers of both mucosal antibodies (Fig. 4) and serum antibodies that recognized a broader range of linear Env epitopes following intranasal administration (Fig. 5) . Similar titers were elicited using a monomeric Env gp120 or trimeric Env gp140 expressed in a DNA prime/protein boost by intramuscular injection (Bower et al., 2005 (Bower et al., , 2004 . These results are supported by a recent study from Grundner et al. (2005) that demonstrated Env gp140 cleavage-defective trimers (similar to the Env gp140 trimers used in this study) are more effective at generating neutralizing antibodies when presented on a solid phase proteoliposomes, indicating that the Env gp140 trimer presented on the surface of a lipid bilayer is a more effective immunogen than nonmembrane-bound Env trimers. However, there are most likely considerable differences between cleaved Env gp160 trimers on our VLPs and uncleaved Env gp140 trimers, even when presented on a lipid membrane.
Linear antibodies elicited in VLP-vaccinated mice were directed to regions in gp120 outside V3, similar to sera from mice vaccinated with Env gp140 proteoliposomes (Grundner et al., 2005) . The role of the V3 region in eliciting neutralizing antibodies has been controversial. Even though V3-specific antibodies can neutralize T-cell-adapted (TCLA) HIV-1 isolates by recognizing a linear site (GPGR/Q), they do tend to be strainspecific (Spenlehauer et al., 1998; York et al., 2001 ). V3-specific antibodies are often elicited using Env gp120 monomers due to sequence accessibility on gp120, but this region is less accessible in oligomeric forms of Env (Bou-Habib et al., 1994; Spenlehauer et al., 1998; Stamatatos and Cheng-Mayer, 1995) and may be less accessible in primary HIV-1 isolates (Burton et al., 2004; Spenlehauer et al., 1998; . Even though few V3-specific linear epitopes were recognized at high titers by sera from mice vaccinated with VLPs, we cannot rule out that antibodies did recognized conformational epitopes in V3. Sera from both soluble Env-and VLP-vaccinated mice were tested in a concanalvin A (Con A) capture ELISA. All serum samples retained high endpoint dilution titers to gp120 (> 1:10 000), indicating that the sera contained antibodies that recognized both conformational epitopes on Env, as well as linear epitopes. The elicited anti-Env antibodies did recognize a cluster of peptides just before (V4-C5 region in gp120) and just after (ectodomain of gp41) the cleavage site.
At lower titers, sera from both soluble Env-or VLPvaccinated mice recognized peptides throughout gp120, including the V1 and V2 regions, however, few of the V1 and V2 peptides were detected at high titers. Three immunodominant peptides in V2 were detected in all VLP-and soluble Envvaccinated mice (peptide 47, representing NDNTSSYR-LISCNTS and peptides 57-58, representing ILKCNDKKF-NGTGPCTNVS). Even though antibodies directed to V1, V2, and/or V3 have been shown to be potent in neutralizing virus in in vitro infection assays (Fung et al., 1992; Gorny et al., 1994; Putney et al., 1986) , the role of these antibodies in protection is unclear and controversial (Calarese et al., 2003; Fung et al., 1992; Gorny et al., 1994 Gorny et al., , 1997 Gorny et al., , 1991 Gorny et al., , 1993 Trkola et al., 1996) .
An interesting set of peptides detected by sera from VLPvaccinated mice was the highly cross-reactive Kennedy epitope (residues 731-752, SRFPDRPEGTEEEGGERDRDRS) located in a region classified as the intra-cytoplasmic domain (ICD) of gp41 (Kennedy et al., 1986) . It has been widely assumed that the ICD is located completely within the inner leaflet of the viral or cellular lipid bilayer. However, neutralizing antibodies are directed to the Kennedy epitope (Cleveland et al., 2000 (Cleveland et al., , 2003 Kennedy et al., 1986; Modrow et al., 1987; Reading et al., 2003) , and at least part of the Kennedy epitope, in the context of intact virions, is reactive with specific monoclonal antibodies and susceptible to protease digestion, consistent with ICD virion or infected cell exposure. Based on antigenic properties and a theoretical structural analyses of Env gp41 ICD sequences from various HIV-1 clades (357 sequences), Hollier and Dimmock recently proposed that ICD sequences potentially form a tail loop structure supported by three β-sheet membrane spanning domains (Hollier and Dimmock, 2005) . Therefore, antibodies directed at this region in Env gp41 would only be elicited by Env gp160 molecules found in particle-based vaccines or from Env gp160 expressed in vivo from DNA plasmids or viral vectors.
We chose to use a mouse model for these studies primarily because this small animal model allows for detailed analysis of both cellular and humoral immunity induced by these VLP vaccines. However, one limitation of sera collected from mice is the intrinsic high titers of non-specific background observed in in vitro neutralization assays. Despite these limitations, sera collected from VLP-vaccinated mice were able to neutralize both neutralization-sensitive and neutralization-resistant viral isolates (Table 1) . Mice vaccinated intranasally with either soluble monomeric Env gp120 or trimeric Env gp140 had neutralizing antibodies to only 89.6. Even though our laboratory and others have demonstrated that trimeric Env gp140 elicits modest levels of neutralizing antibodies, the lack of neutralizing antibodies from soluble Env-vaccinated mice may be a result of the route of inoculation [mucosal (intranasal) vs. parenteral (intramuscular/intradermal)]. The neutralizing capacity of sera collected from VLP-vaccinated mice was specific for the HIV-1 envelope, since this serum did not neutralize virus pseudotypes with MuLV Env (Table 1 ). These HIV-1 Env-specific neutralizing antibody titers were above the background neutralizing antibodies directed against cellular monkey proteins embedded in the VLP membrane, since sera from mice vaccinated with Gag only particles (no envelope) elicited few antibodies, which were subtracted from the final analysis.
Recently, Hammonds et al. recorded high levels of neutralizing antibodies to cellular embedded proteins in VLP-vaccinated guinea pigs following intramuscular injection (Hammonds et al., 2005) , but significant neutralizing titers were still present following depletion of the non-specific neutralizing antibodies. The reasons for the differences in neutralizing capacity in the sera from these two studies are unclear, but may be due to the route of inoculation (intranasal vs. intramuscular), the amount of Env on each of the particles, the animal species used (mice vs. guinea pigs), or the phenotype of the envelope isolates used . These differences are unlikely a result of the neutralization assay used, since both studies used the same TZM-bl assay . No neutralizing antibodies were detected in the lung washes from our vaccinated mice, which may be directly due to the mouse model used or the low titers of mucosal antibodies detected (Fig. 4) . Future studies in larger rodents (rabbits or guinea pigs) or non-human primates will be necessary to determine if VLPs elicit neutralizing antibodies in mucosal tissues.
Why might the VLPs described in this study be such effective mucosal immunogens? Compared to particulate antigens, intranasal vaccination of soluble proteins, in the absence of an adjuvant, induces low or undetectable immune responses in rodents and primates (Tochikubo et al., 1998) . Intranasal immunization of VLPs induces both systemic and mucosal immunity. Soluble antigens can penetrate the nasal epithelium and directly interact with dendritic cells, macrophages and lymphocytes and then these antigens are transferred to posterior lymph nodes (Tilney, 1971) . In contrast, VLPs are most likely phagocytosed by microfold epithelial cells (M cells) in the nasal lumen and then directly deposited to the NALT (nasal associated lymphoid tissue) via M cell transcytosis (Wu et al., 1997) , which preferentially drains into lymph nodes. This process induces strong local (NALT) and distant immune responses in both peripheral and mucosal immune compartments (Sminia and Draal, 1999) . Soluble antigens bypass the NALT and are directly fed into superficial lymph nodes by antigen presenting cells in the nasal lumen resulting in a lower local immune response (Sminia and Draal, 1999) . Therefore, VLP immunogens directly interact with the mucosal immune system to elicit high titer immunity. Overall, the expression of Env in any HIV/AIDS vaccine may elicit a variety of potentially effective protective immunity depending on the structure of the protein presented to the immune system. Following mucosal administration, the membrane-bound Env on the surface of a particle appears more effective at eliciting immunity that specifically recognizes Env on the native particle compared to the immunity elicited by soluble monomers or trimers of Env.
Materials and methods
DNA plasmids
The pTR600 vaccine plasmid (Green et al., 2003) and the VLP expressing plasmid, pHIV-VLP, have been previously described (Young et al., 2004) . Briefly, the pTR600 vector was constructed to contain the cytomegalovirus immediate-early promoter (CMV-IE) for initiating transcription of eukaryotic inserts and the bovine growth hormone polyadenylation signal (BGH poly A) for termination of transcription. The vector contains the Col E1 origin of replication for prokaryotic replication and the kanamycin resistance gene (kan r ) for selection in antibiotic media.
The pHIV-VLP plasmid (Young et al., 2004) encodes for the following gene sequences: HIV-1 BH10 gag-pol (pHIV BH10 nt 112-3626) (accession number M1564) and HIV-1 ADA vpu, env, rev, tat (nt 5101-8159). Briefly, the pHIV-VLP was constructed from two subclones encoding for the 5′ end of the VLP gene insert (5′-ClaI and 3′-EcoRI) and a second subclone encoding for the 3′ end of the VLP gene insert (5′-EcoRI and 3′-NheI). Oligonucleotides corresponding to the gag-pol sequences were used in a PCR reaction to amplify a fragment of DNA (5′ PCR product) composed of the 5′ untranslated leader sequence (105 nucleotides) and gag-pol sequences (ATG start codon of gag to the TAG stop codon at the 3′ end of the reverse transcriptase sequence, pHIV BH10 nt 112-3626). Both of the 5′ and 3′ PCR products were cloned into pTR600 using unique restriction enzymes sites (5′ PCR product: ClaI and EcoRI and the 3′ PCR product using EcoRI and NheI). The splice-acceptor sites were not mutated to allow for efficient mRNA processing of singly and multiply spliced messenger RNAs. The previously described safety mutations were introduced into the VLP vaccine insert by PCR-based mutagenesis (Stratagene, La Jolla, CA) to delete RT activity, RNase H activity, and packaging of RNA genome (Young et al., 2004) .
Plasmids expressing the HIV-1 NL4-3 Gag gene products only, pGag p55 , were derived from codon-optimized sequences (phGag), as previously described (Huang et al., 2001; Young et al., 2004) . pGag p55 encodes for an immature, unprocessed HIV-1 Gag particle. The plasmids, pEnv gp120 and pEnv gp140(FT) , encode for soluble forms of monomeric Env gp120 or trimeric Env gp140 from the isolate ADA (Bower et al., 2005 (Bower et al., , 2004 . Each plasmid was amplified in Escherichia coli strain-DH5 alpha, purified using anion-exchange resin columns (Qiagen, Valencia, CA), and stored at − 20°C in dH 2 O. Plasmids were verified by appropriate restriction enzyme digestion and gel electrophoresis. Purity of DNA preparations was determined by optical density reading at a wavelength of 260 and 280 nm.
Transfections and expression analysis
The monkey fibroblast cell line COS (5 × 10 5 cells/ transfection) was transfected with 2 μg of DNA using 12% lipofectamine according to the manufacturer's guidelines (Life Technologies, Grand Island, NY). Supernatants (2 ml) were collected and stored at − 20°C. Cell lysates were collected in 500 μl of 1% Triton X-100 and stored at − 20°C. Quantitative antigen capture ELISAs were conducted according to the manufacturer's protocol (Perkin-Elmer Life Sciences, Boston, MA). For Western hybridization analysis, 3.3% of supernatant and 1.5% of the cell lysate were diluted 1:2 in SDS sample buffer (Bio-Rad, Hercules, CA), boiled for 5 min, and loaded onto a 10% polyacrylamide/SDS gel. The resolved proteins were transferred onto a nitrocellulose membrane and incubated with a 1:10 000 dilution of polyclonal antisera using HIV-Ig to detect HIV-1 antigens diluted in PBS containing 0.05% Tween 20 and 5% nonfat dry milk. After extensive washing, bound human antibodies were detected using a 1:10 000 dilution of horseradish peroxidase-conjugated goat anti-human antiserum, followed by enhanced chemiluminescence (Amersham, Buckinghamshire, UK).
Purification of virus-like particles and soluble envelopes
Supernatants from COS cells, transiently transfected with plasmid expressing Gag or VLPs were pelleted via ultracentrifugation (100,000 × g through 20% glycerol, weight per volume) for 2 h at 4°C. The pellets were subsequently resuspended in PBS and overlaid onto 20-60% sucrose gradients (11 steps, 4% increments) and ultracentrifuged for 17 h at 100,000×g at 4°C. Eleven fractions (20-60%, 1 ml, weight per volume) were collected top to bottom from the gradient, and the proteins were precipitated with equal volumes of 20% trichloroacetic acid (TCA) and subjected to SDS-PAGE and immunoblotting. The viral proteins were detected by primary antisera via Western hybridization. Determination of the amount of Gag and Env protein on the particle was determined by ELISA, as previously described . Soluble monomeric Env gp120 or trimeric Env gp140 was purified from the supernatant of transiently transfected COS cells by a lectin column and resuspended in 0.9% saline for inoculation.
Immunization of mice
Female BALB/c mice (n = 6, 5-7 weeks old) were immunized at weeks 0, 3, and 6 with purified VLPs (40 μg total protein) and co-inoculated with phosphorothioate CpG oligodeoxynucleotides (CpG ODNs, 10 μg each) via the nares. Each CpG ODN (ODN-1: 5′-TCCATGACGTTCCTGACGTT-3′, ODN-2: 5′-TGACTGTGAACGTTCGAGATGA-3′) (Gallichan et al., 2001; Horner et al., 1998; Kang and Compans, 2003; McCluskie and Davis, 1998; Moldoveanu et al., 1999) was synthesized and purified by high-pressure liquid chromatography (Sigma-Genosys, The Woodlands, TX, USA). The CpG ODNs were resuspended in sterile dH 2 O (2 μg/μl) and stored at − 80°C. Each purified VLP preparation was analyzed for purity by silver staining of an SDS-PAGE and ∼80-90% of the protein in the purified preparation was Gag gene products and therefore, mice were administered ∼ 0.5-1.0 μg of Env per VLP immunization. Mice were administered VLPs in sterile PBS plus CpG ODNs into the nares of each mouse (30 μl total volume). Supernatants from primate cells transiently transfected with the vector, pTR600, were ultracentrifuged through 20% glycerol. For intranasal inoculation, the pellet was resuspended in sterile PBS plus CpG ODNs and inoculated into the naïve mice (equivalent volume compared to mice given a VLP inoculum). Mice vaccinated with Env gp140 or Env gp120 were given 1 μg or 10 μg of protein with the same concentration of CpG ODNs in PBS. Proteins were purified from the supernatant of transiently transfected cells with plasmids expressing a 6× HIS-tagged envelopes (Bower et al., 2005 (Bower et al., , 2004 . Gag p24 was purified by the same ultracentrifugation procedure as VLPs. Mice were administered the same amount of Gag p24 plus CpG ODNs to match the Gag p24 in the VLP inoculations (40 μg). Mice were housed in compliance with USDA regulations and were monitored daily for weight loss, behavior, and adverse reaction. Mice were partially anesthetized with xylazine (20 mg/ml) and ketamine (100 mg/ml) administered subcutaneously in the abdomen prior to immunization.
Collection of samples
Blood samples were collected by retro-orbital plexus puncture on day 1 and weeks 2, 5, and 8 post-immunization on anesthetized mice. Sera samples were collected by centrifugation (5000 rpm, 10 min) and stored at − 20°C. Mucosal washings were collected at week 9 post-immunization. Vaginal lavages were collected by repeated rinsing of the vagina (200 μl) with sterile PBS. The lungs were excised and cut into small pieces using a sterile scalpel in sterile PBS (200 μl). The lung tissue pieces were centrifuged (12,000 rpm, 5 min), and supernatants were collected. A section of the intestines (1.3 cm) was aseptically removed and placed in sterile PBS (200 μl). The collected fecal samples were disrupted using a sterile pipet tip, vortexed (15 s), centrifuged (12,000 rpm for 5 min), and the product supernatants were collected. The protein concentration of the fecal supernatants was adjusted to a final concentration of 1 mg/ml with sterile PBS. All samples were stored at − 80°C.
ELISpot assays
Spleens were harvested from vaccinated mice at week 8, and splenocytes were isolated for ELISpot assays, as previously described (Bower et al., 2005 (Bower et al., , 2004 . Briefly, splenocytes were depleted of erythrocytes by treatment with ammonium chloride (0.1 M, pH 7.4). Following thorough washing with PBS, cells were resuspended in RPMI medium with 10% fetal bovine serum (cRPMI). Cell viability was determined by trypan blue exclusion staining. The number of anti-Gag, anti-Pol, or anti-Env gp160 -specific murine INF-γ (mINF-γ) secreting splenocytes was determined by enzyme-linked immunospot (ELISpot) assay (R&D Systems, Minneapolis, MN, USA). Briefly, pre-coated anti-mIFN-γ plates were incubated (25°C for 2 h) with cRPMI (200 μl) and then were incubated with splenocytes (1 × 10 6 /well) isolated from vaccinated mice. Splenocytes were stimulated (48 h) with peptides (AIDS Reagent and Reference Program) representing the consensus clade B Gag or Pol regions. For Env, four pools of peptides were used, (1) a pool of 10 peptides representing the C1 region of Env (amino acids 32-79), (2) a pool of 4 peptides representing the V3 region of Env (amino acids 294-314), (3) a pool of 99 peptides representing the gp120 region (amino acids 52-455) or (4) a pool of 99 peptides representing the gp41 region (amino acids 444-840) of the consensus Group M Env protein. The V3 regions peptides were specific to the sequence for the isolates, MN, IIIB, the subtype B, and the consensus B sequences. The subtype B and consensus B match the V3 loop of ADA. Additional wells of splenocytes were stimulated with PMA (50 ng)/ionomycin (500 ng) or were mock stimulated. In addition, IL-2 was added to all wells (10 units/ml). Plates were washed with PBS-Tween (3×) and were incubated (25°C for 2 h) with biotinylated anti-mIFN-γ and incubated (4°C for 16 h). The plates were washed and incubated (25°C for 2 h) with streptavidin conjugated to alkaline phosphatase. Following extensive washing, cytokine/antibody complexes were incubated (25°C for 1 h) with stable BCIP/NBT chromogen. The plates were rinsed with dH 2 O and air dried (25°C for 2 h). Spots were counted by an ImmunoSpot ELISpot reader (Cellular Technology Ltd., Cleveland, OH, USA).
Antibody response to VLP immunizations
Serum and mucosal samples were individually collected and tested for antibody (IgG or IgA) responses to Env by ELISA. HIV-1 ADA Env gp120 was purified from the supernatants collected from 293T cells transiently transfected with a plasmid that expressed the HIV-1 ADA Env gp120 from codon optimized gene inserts. Each well of a 96-well plate was coated with 50 ng Env gp120 per well (4°C for 16 h). Plates were blocked (25°C for 2 h) with PBS containing Tween 20 (0.05%) and nonfat dry milk (5%) and then incubated with serial dilutions of each sample (sera or mucosal washings) (25°C for 2 h). Following thorough washing in PBS-Tween 20 (0.05%), samples were incubated (25°C for 1 h) with goat anti-mouse IgG conjugated to horseradish peroxidase (HRP) diluted 1:5000 in PBS-Tween 20 (0.05%) and nonfat dry milk (5%). The unbound antibody was removed, and the wells were washed. Samples were incubated with TMB substrate (1 h), and the colorimetric change was measured as the optical density (O.D., 405 nm) by a spectrophotometer (Dynex Technologies, Chantilly, VA, USA). The O.D. value of naïve sera and sera from mice vaccinated with virus-like particles composed of only Gag gene products (no Env) was subtracted from the samples using antisera from vaccinated mice. Results were recorded as the arithmetic mean ± the standard deviation (SD). In order to measure the level of HIV-1 Env-specific IgG subtypes, biotinylated goat anti-mouse IgG 1 or IgG 2a (1:5000) antibodies were used to detect Env-antibody complexes.
Mapping of specific antibodies by poly-L-lysine peptide ELISA Antibody reactivity to HIV peptides was determined using a poly-L-lysine (PLL) peptide ELISA, as previously described (Ball et al., 1994; Cole et al., 2000; Miller et al., 1992) . Briefly, the wells of Immulon 1B microtiter plates (Dynex Corporation, McLean, VA) were coated with 2 μg per well of PLL (Sigma, St. Louis, MO) diluted in 0.05 M sodium bicarbonate buffer (pH 9.6) and incubated for 1 h at 25°C. Peptides were diluted to 50 μg/ml in 0.05 M sodium bicarbonate buffer (pH 9.6) were then fixed onto PLL-coated wells by incubating 50 μl per well overnight at 25°C. After ∼16 h, all wells were washed and blocked with 100 μl of glycine (1 M) followed by 0.5% nonfat dry milk/0.5% gelatin for 1 h each at room temperature. Serum was diluted 1:3000 in 5% nonfat dry milk and incubated for 1 h at room temperature. The wells were extensively washed and incubated with goat anti-mouse IgG-HRP diluted 1:5000 in 5% nonfat dry milk for 1 h at 25°C. Specific reactivity was detected by the addition of 100 μl TMB substrate (Sigma, St. Louis, MO, USA). The reaction was stopped by the addition of 50 μl of sulfuric acid (1 N) and read as O.D. at 450 nm. Antibody reactivity was then reported as the O.D. at 450 nm at 1:3000 dilution of sera.
Pseudovirus preparation
HIV-1 viral cores were pseudotyped with envelopes representing primary R5 isolates (ADA, YU-2, CAAN5342. A2, PVO.4, and THRO4156.18) or R5X4 isolates (89.6). Briefly, 293T cells were transfected with 5 μg of Env encoding plasmid and 10 μg of an Env-deficient HIV-1 backbone vector (pSG3Δenv) using Lipofectamine 2000 (Invitrogen) . Virus-containing supernatant was collected 48 h posttransfection, clarified of cellular debris by centrifugation (14,000 rpm for 10 min) and stored at − 80°C in 1 ml aliquots. TCID 50 was determined using 5-fold dilutions of virus. Eight hours prior to infection, TZM-bl cells were plated at a concentration of 1 × 10 4 cells per well. Cells were incubated with serial dilutions of virus for 48 h at 37°C in 5% CO 2 . Cell lysates were harvested and incubated (20 min) in lysis buffer (25 mM Tris phosphate, pH = 7.8, 2 mM DTT, 2 mM 1-2-diaminocyclohexane-N,N,N′,N′-tetraacetic acid, 10% glycerol, 1% Triton X-100). Infectivity was determined by measuring the relative light units (RLU) using a Femtomaster FB12 Luminometer (Zylux, Maryville, TN). The TCID 50 was calculated from the RLU values.
Neutralization assay
Antisera from vaccinated mice were tested for the ability to neutralize virus infection in vitro using TZM-bl cells indicator cells Montefiori, in press ). These cells express human CD4 (hCD4), human CCR5 (hCCR5), human CXCR4 (hCXCR4), and a luciferase reporter driven by the HIV-1 LTR. TZM-bl cells were cultured in cDMEM with 10% fetal calf serum (10%) (Atlanta Biologicals, Atlanta, GA, USA). TZM-bl cells were plated at a concentration of 1 × 10 4 cells per well and incubated in DMEM with 10% FCS (8 h). Equal volumes of serial dilutions of each antiserum and pseudovirus were incubated for at least 1 h at 37°C. Media was removed from the TZMbl cells and replaced with the antiserum/pseudovirus mixture. The cells were then incubated for 48 h at 37°C in 5% CO 2 . Cell lysates were harvested and incubated in lysis buffer (20 min). Virus neutralization by mouse antiserum was determined by measuring the relative light units (RLU) using a Femtomaster FB12 Luminometer (Zylux, Maryville, TN). Neutralization by naïve sera and sera from mice vaccinated with virus-like particles composed of only Gag gene products (no Env) or MuLV Env was subtracted from the RLU from assays using antisera from vaccinated mice. All samples were tested in duplicate.
